Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.60 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.60 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.60 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.60 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | TACR2 | P21452 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 3/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.43 |
| ▸ | CDC25A | P30304 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19101977 | 1.00 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL3467442 | 1.00 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL19101982 | 1.00 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL15960190 | 1.00 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13005442 | 1.00 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL18542464 | 1.00 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13005383 | 1.00 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL21440458 | 1.00 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL21082185 | 1.00 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL38652118 | 1.00 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651903-A1 | M6PR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| CN-113164501-B | Use of agonist ligands for IGF-2 receptor for the treatment of An Geman syndrome and autism | 纽约大学 | 2024-08-09 | — | — | CN | disclosed |
| WO-2024155748-A1 | M6PR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| EP-4370156-A1 | M6PR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4356964-A2 | USE OF IGF-2 RECEPTOR AGONIST LIGANDS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM | New York University (US) | 2024-04-24 | — | — | EP | disclosed |
| CN-117915956-A | M6PR cell surface receptor binding compounds and conjugates | 利西亚治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-3833358-B1 | USE OF IGF-2 RECEPTOR AGONIST LIGANDS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM | UNIV NEW YORK (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023288015-A1 | M6PR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| EP-4087584-A2 | CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-112912102-A | Use of mannose-6-phosphate and modifications thereof to enhance memory and reduce memory impairment | 纽约大学 | 2021-06-04 | — | — | CN | disclosed |
| US-20130164387-A9 | NOVEL MANNOPYRANOSIDE DERIVATIVES WITH ANTICANCER ACTIVITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-06-27 | — | — | US | disclosed |
| US-20120269903-A1 | NOVEL MANNOPYRANOSIDE DERIVATIVES WITH ANTICANCER ACTIVITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-10-25 | — | — | US | disclosed |
| US-20110112044-A1 | NOVEL USES OF D-MANNOPYRANOSE DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-05-12 | — | — | US | disclosed |
| US-7208611-B2 | Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use | XENOPORT, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060205677-A1 | Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use | XENOPORT, INC. | 2006-09-14 | — | — | US | disclosed |
| WO-2006091790-A1 | PLATINUM-CONTAINING COMPOUNDS EXHIBITING CYTOSTATIC ACTIVITY, SYNTHESIS AND METHODS OF USE | XENOPORT, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-0545198-B1 | Peptides with insulin like activity | HOECHST AG (DE) | 1999-09-15 | — | — | EP | disclosed |
| US-5622934-A | TREATING DIABETES MELLITUS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-04-22 | — | — | US | disclosed |
| EP-0545198-A2 | Peptides with insulin like activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205677-A1 | Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use | TYMP, TOP1, TOP2A | SSTR1 4740/4885SSTR2 4809/4885SSTR4 4747/4885 |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | SSTR1 347/4885SSTR2 704/4885SSTR4 239/4885 |
| US-20130164387-A9 | NOVEL MANNOPYRANOSIDE DERIVATIVES WITH ANTICANCER ACTIVITY | MAN2A1, MANBA, MAN2B1 | SSTR1 4137/4885SSTR2 3782/4885SSTR4 4057/4885 |
| US-20110112044-A1 | NOVEL USES OF D-MANNOPYRANOSE DERIVATIVES | M6PR, BMP6, DCPS | SSTR1 1791/4885SSTR2 2335/4885SSTR4 1290/4885 |
| US-20120269903-A1 | NOVEL MANNOPYRANOSIDE DERIVATIVES WITH ANTICANCER ACTIVITY | MAN2A1, MANBA, MAN2B1 | SSTR1 4137/4885SSTR2 3782/4885SSTR4 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.